Key Points
- LivaNova CFO Alex Shvartsburg sold 2,500 shares for $227,275 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 5.6% to 42,147 shares.
- The company beat quarterly expectations, reporting EPS of $1.23 versus $1.06 expected and revenue of $393.15 million; revenue rose 9.9% year over year.
- Analysts hold a consensus Moderate Buy rating with a $101.22 average price target; nine analysts rate the stock Buy and three rate it Hold.
LivaNova PLC (NASDAQ:LIVN - Get Free Report) CFO Alex Shvartsburg sold 2,500 shares of the business's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $90.91, for a total transaction of $227,275.00. Following the completion of the sale, the chief financial officer owned 42,147 shares in the company, valued at approximately $3,831,583.77. This trade represents a 5.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
LivaNova Price Performance
NASDAQ LIVN traded up $1.12 on Friday, reaching $91.32. The company's stock had a trading volume of 742,276 shares, compared to its average volume of 764,040. LivaNova PLC has a twelve month low of $52.37 and a twelve month high of $99.38. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.22 and a current ratio of 1.46. The stock has a market cap of $5.03 billion, a PE ratio of 30.44 and a beta of 0.91. The firm's 50 day moving average is $80.32 and its two-hundred day moving average is $74.22.
LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.17. The company had revenue of $393.15 million during the quarter, compared to analyst estimates of $381.13 million. LivaNova had a net margin of 13.01% and a return on equity of 16.10%. The business's revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.11 EPS. As a group, sell-side analysts predict that LivaNova PLC will post 3.76 EPS for the current year.
Institutional Trading of LivaNova
Institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new position in LivaNova in the 2nd quarter worth approximately $1,418,000. Avidian Wealth Enterprises LLC purchased a new position in LivaNova during the 3rd quarter worth approximately $752,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in LivaNova during the 2nd quarter valued at $4,053,000. Maverick Capital Ltd. acquired a new stake in LivaNova during the 1st quarter valued at $956,000. Finally, Renaissance Technologies LLC raised its stake in LivaNova by 15.7% during the 1st quarter. Renaissance Technologies LLC now owns 183,000 shares of the company's stock valued at $11,631,000 after purchasing an additional 24,900 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.
Analysts Set New Price Targets
Several analysts recently commented on LIVN shares. Needham & Company LLC increased their target price on shares of LivaNova from $93.00 to $112.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. Zacks Research lowered shares of LivaNova from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 19th. Raymond James Financial set a $120.00 price target on LivaNova in a report on Wednesday, November 4th. Robert W. Baird increased their price objective on LivaNova from $95.00 to $111.00 and gave the company an "outperform" rating in a research report on Thursday, November 5th. Finally, Barclays raised their price objective on LivaNova from $105.00 to $120.00 and gave the stock an "overweight" rating in a research note on Monday, November 9th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $101.22.
Check Out Our Latest Stock Report on LivaNova
LivaNova Company Profile
(
Get Free Report)
LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova's VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
